Insulin Can Be Given Subcutaneously Using Different Types of Delivery Devices Such As Pens and Pumps
![]() |
Insulin Delivery Devices |
Insulin Delivery Devices system that is both minimally
invasive or noninvasive and most physiological. The first noninvasive and
alternate method of delivering insulin to be approved was through inhalation,
although this method has since been taken. Technology for noninvasive insulin
delivery is currently being researched. Oral, buccal, nasal, peritoneal, and
transdermal insulin delivery methods are among those being studied. The past,
present, and future of various insulin administration systems are the main
topics of this review study.
Insulin Delivery Devices can be administered subcutaneously using a variety of devices, including insulin pens, insulin pumps, and vials and syringes. Despite being the most common way to provide insulin, subcutaneous insulin delivery is linked to injection pain, needle anxiety, lipodystrophy, noncompliance, and peripheral hyperinsulinemia.
Depending on the insulin dosage, the syringe's
capacity should be chosen.The needle length and gauge are additional elements
that should be modified for comfort.
Recent developments in continuous glucose monitoring
(CGM) and computer algorithms have given the development of closed-loop
delivery systems a boost. The evolution of needles, tethered and patch Insulin
Delivery Devices pumps, bionic pancreas, alternate
controller-enabled infusion (ACE) pumps, and do-it-yourself artificial pancreas
systems (DIY-APS) is covered in this review.
Insulin
Delivery Devices By product type (insulin syringes,
insulin pens (reusable and disposable), insulin pumps (tethered/external pumps,
patch pumps), insulin injectors, and others), the insulin delivery devices is
segmented. By End-User (Hospitals, Diabetes Centres, and Other Institutions),
Geography is expected to grow by
The rising prevalence of diabetes among the general
population is the main reason driving growth in the insulin delivery devices. Additionally,
according to the NCBI 2020 article Prevalence and incidence of type 1 diabetes
in the world: a systematic review and meta-analysis by Mobasseri M. et al., the
development and approval of advanced insulin delivery devices for the treatment
of type I diabetes, which has an incidence of 15 per 100,000 people and a
prevalence of 9.5% worldwide, is also anticipated to fuel the global insulin
delivery device.
In this sector, technological breakthroughs and
innovations are a persistent trend. The widespread acceptance of recently
introduced novel pen devices and portable pumps is being aided by the strong
demand for sophisticated insulin delivery systems, which is expected to accelerate
expansion. positive reimbursement guidelines for these devices,
|
|
Comments
Post a Comment